Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Direct Meds
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict82/ 100
Grade B− · #30Direct Meds
One of the rare programs offering an oral/sublingual route on both molecules with all-inclusive pricing — marked down hard because the numbers are company-stated rather than independently verified, and the company carries an FDA warning letter from September 2025.
Visit Direct MedsThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 82/100 (grade A vs B−). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Direct Meds still earns its place — needle-averse patients who specifically want a sublingual GLP-1 option and are willing to vet a newer operator themselves.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results80
92
Real-world results80
97Price honesty82
97
Price honesty82
96Prescriber access80
96
Prescriber access80
88Formulary choice88
88
Formulary choice88
95Cancellation fairness82
95
Cancellation fairness82
93Member support80
93
Member support80
Price, coverage & features
| Metric | CoreAge Rx | Direct Meds |
|---|---|---|
| Verdict Score | 94/100 | 82/100 |
| Grade | A | B− |
| Semaglutide | $99/mo | $179/mo |
| Tirzepatide | $149/mo | $224/mo |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Direct Meds
What we like
- Rare oral/sublingual drops on both molecules — sublingual semaglutide from $179/mo and tirzepatide from $224/mo — plus an injectable path
- All-inclusive pricing with no separate membership fee to layer on top
- Covers both semaglutide and tirzepatide rather than a single molecule
The caveats
- Every option is compounded, not FDA-approved
- Pricing is company-stated (from a press release) and not independently verified — treat the figures as claims, not confirmed rates
- Newer entity (est. 2024) operating across several similar-looking domains, so confirm you're on the right one
- States served are not disclosed, so coverage can't be verified before you sign up
- FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025; it is public in FDA's warning-letter database
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Needle-averse patients who specifically want a sublingual GLP-1 option and are willing to vet a newer operator themselves.
Visit Direct Meds Read the full Direct Meds review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Direct Meds does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.